Article

Comparative study finds early vision benefits for intravitreal triamcinolonetreatment of occult CNV

Ft. Lauderdale-Results from a prospective, comparative study indicateintravitreal triamcinolone acetonide 25 mg may improve visual outcome insome patients with exudative AMD, reported Jost B. Jonas, MD, of the Universityof Heidelberg, Germany.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Related Content
Optigo Bio receives People’s Choice Award for its proprietary drug anchoring
May 9th 2025

Optigo Bio receives People’s Choice Award for its proprietary drug anchoring

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Results of phase 2 clinical SAGA study of oral gildeuretinol for GA presented at ARVO 2025
May 8th 2025

Results of phase 2 clinical SAGA study of oral gildeuretinol for GA presented at ARVO 2025

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP
May 8th 2025

Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP

Assessment of AI-enabled screening for ROP in low-resource settings
May 8th 2025

Assessment of AI-enabled screening for ROP in low-resource settings

© 2025 MJH Life Sciences

All rights reserved.